An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

SIMPLE SUMMARY: Microsatellite instability-high (MSI-H) is an established biomarker for response to immune checkpoint inhibitors (ICIs). ICIs are not usually administered in the first-line setting for MSI-H tumors including gastric cancer (GC), although such tumors tend to be less responsive to cyto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Kawakami, Hisato, Hironaka, Shuichi, Esaki, Taito, Chayama, Kazuaki, Tsuda, Masahiro, Sugimoto, Naotoshi, Kadowaki, Shigenori, Makiyama, Akitaka, Machida, Nozomu, Hirano, Hidekazu, Hirata, Kenro, Hara, Hiroki, Yabusaki, Hiroshi, Komatsu, Yoshito, Muro, Kei
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7918984/
https://ncbi.nlm.nih.gov/pubmed/33671871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040805
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados